IPO roundup: MAP Pharma’s mixed reception, other recent filings
MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than the $92 million it might… Continue Reading
Life sciences briefing: Friday, Sept. 21, 2007
Featured companies: CG Therapeutics, Complete Genomics, ConforMIS, Flexible Medical Systems, LeMaitre Vascular, MAP Pharmaceuticals, ParaPro, Vascular Architects, Zars Pharma
(UPDATED on 10/1/07: See below.)
[NOTE: Posting has been slow recently for personal reasons. I'll be doing my best to catch up today.]
Complete Genomics raises funding for high-speed sequencing —… Continue Reading
MAP Pharma charts course for $86M IPO
MAP Pharmaceuticals, a Mountain View, Calif., developer of reformulated drugs for inhalation, filed to raise up to $86 million in an initial public offering. The company’s registration statement with the SEC is here.
MAP is the latest drugmaker to brave the IPO waters, which have been… Continue Reading
MAP Pharma raises $50M for respiratory and CNS disease treatments
MAP Pharmaceuticals, a Mountain View, Calif, developer of treatments for respiratory and central-nervous-system diseases, said it raised $50 million in a fourth round of venture funding.
See statement here.
New investor, the D.E. Shaw group, joined previous investors, including Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital,… Continue Reading